Art. -Nr.: HY-12116

L-NIL

Name: L-NIL
Brand: MedChemExpress
SKU: HY-12116
Price: 90.00 USD
Availability: InStock
Rating: 5 (10 reviews)

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

L-NIL is an inducible NO synthase inhibitor, with an IC₅₀ of 3.3 μM for miNOS.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.82%
CAS. Nr.: 53774-63-3
Formel: C₈H₁₇N₃O₂
Molecular Weight:187.24

Speicherung:

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

L-NIL Chemical Structure

CAS. Nr.: 53774-63-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

L-NIL is an inducible NO synthase inhibitor, with an IC₅₀ of 3.3 μM for miNOS^[1]^[2]^[3].

IC₅₀ & Target

iNOS

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	0.13 μM Compound: 3	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells	[PMID: 11327580]
DLD-1	IC₅₀	470 mM Compound: 3	Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells	[PMID: 11327580]
DLD-1	IC₅₀	2.8 μM Compound: 3	Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells	[PMID: 12620067]
DLD-1	IC₅₀	280 nM Compound: 1	Inhibition of human iNOS expressed in human DLD1 cells after 1 hr Inhibition of human iNOS expressed in human DLD1 cells after 1 hr	[PMID: 18024030]
DLD-1	IC₅₀	31 μM Compound: 1	Inhibition of cytokine-induced iNOS activity in human DLD1 cells after 24 hrs Inhibition of cytokine-induced iNOS activity in human DLD1 cells after 24 hrs	[PMID: 18024030]
HUVEC	IC₅₀	2.4 μM Compound: 3	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells	[PMID: 11327580]
RAW264.7	IC₅₀	>200 μM Compound: L-NIL	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method	[PMID: 14510614]
RAW264.7	IC₅₀	18.6 μM Compound: L-NIL	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method	[PMID: 14510614]
RAW264.7	IC₅₀	20.14 μM Compound: L-NIL	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24360561]
RAW264.7	IC₅₀	15.8 μM Compound: L-NIL	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
RAW264.7	IC₅₀	7.5 μM Compound: L-NIL	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 27588583]
RAW264.7	IC₅₀	28.29 μM Compound: L-NIL	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay	[PMID: 29102229]
RAW264.7	IC₅₀	15.8 μM Compound: L-NIL	Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells after 24 hrs by Griess assay	[PMID: 29799195]
RAW264.7	IC₅₀	1.55 μM Compound: NIL	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 29932657]
RAW264.7	IC₅₀	7 μM Compound: L-Nil	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based colorimetric method Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess reagent based colorimetric method	[PMID: 30724564]
Sf9	IC₅₀	2500 nM Compound: 1	Inhibition of human eNOS expressed in insect SF9 cells after 1 hr Inhibition of human eNOS expressed in insect SF9 cells after 1 hr	[PMID: 18024030]
Sf9	IC₅₀	6 μM Compound: 1	Inhibition of human nNOS expressed in insect SF9 cells after 1 hr Inhibition of human nNOS expressed in insect SF9 cells after 1 hr	[PMID: 18024030]

In Vitro

L-NIL produces a concentration-dependent inhibition of both the mouse inducible NOS (miNOS) and the rat brain constitutive NOS (rcNOS) and is considerably more potent for miNOS. The IC₅₀ values for L-NIL with miNOS and rcNOS are 3.3 and 92 pM, respectively, indicating that L-NIL is 28-fold more selective for miNOS. In addition, L-NIL has approximately 6-fold greater potency for miNOS than either L-NMA or L-NNA^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

L-NIL (10 and 30 mg/kg, IP) prevents the inflammation, oxidative stress and autophagy induced by renal IR in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Balb/c (20-25 g)^[1].
Dosage:

10 and 30 mg/kg.
Administration:

Intraperitoneally at the end of CLP and at 6 h after sepsis induction.
Result:

Led to a negligible increase in plasma NGAL compared to sham mice.
Led to a significant decrease in both TLR4 and IL1β protein contents and clusterin transcript.
Showed an increase in NFAT5 mRNA levels, as compared with mice treated with vehicle.
Promoted a decrease in AR protein expression, as compared with animals treated with vehicle.

Chemical Information

CAS. Nr. 53774-63-3
Appearance Solid
Molecular Weight 187.24
Formel C₈H₁₇N₃O₂
Color White to off-white
SMILES

N[C@@H](CCCCNC(C)=N)C(O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (10)

All WB

Sort by:

Journal Impact Factor

Nat Biomed Eng

Activatable near-infrared probes for the detection of specific populations of tumour-infiltrating leukocytes in vivo and in urine. [Abstract]

2023 Mar;7(3):281-297. PMID: 36941352
Nat Commun

Host glutathione is required for Rickettsia parkeri cell division and intracellular survival. [Abstract]

2025 Jul 1;16(1):5547. PMID: 40593553
J Adv Res

iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation. [Abstract]

2023 Jan:43:175-186. PMID: 36585107

L-NIL purchased from MedChemExpress. Usage Cited in: J Adv Res. 2023 Jan:43:175-186. [Abstract]

Inhibiting iNOS with L-NIL (10 μM) blunted the adverse effect of iNOS expression in cardiomyocytes.
Sci Transl Med

SARS-CoV-2 induces neutrophil degranulation and differentiation into myeloid-derived suppressor cells associated with severe COVID-19. [Abstract]

2025 May 21;17(799):eadn7527. PMID: 40397714
Cancer Lett

Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGFβ-dependent squamous cell carcinoma lung metastasis. [Abstract]

2023 Aug 28:570:216330. PMID: 37524225
Free Radic Biol Med

Cigarette smoke induces the ROS accumulation and iNOS activation through deactivation of Nrf-2/SIRT3 axis to mediate the human bronchial epithelium ferroptosis. [Abstract]

2023 May 1:200:73-86. PMID: 36871899
J Agric Food Chem

Quercetin Inhibits Neuronal Pyroptosis and Ferroptosis by Modulating Microglial M1/M2 Polarization in Atherosclerosis. [Abstract]

2024 May 29;72(21):12156-12170. PMID: 38755521
Exp Eye Res

INOS ablation promotes corneal wound healing via activation of Akt signaling. [Abstract]

2024 Jun:243:109886. PMID: 38583755
Biochem Biophys Res Commun

Exploring the role of iNOS in HFpEF-Related myocardial fibrosis: Involvement of PTEN-PI3K/AKT signaling pathway. [Abstract]

2024 Nov 19:734:150589. PMID: 39245028
bioRxiv

A genetic screen identifies O-antigen as essential for Rickettsia parkeri survival in macrophages by protecting from inflammasomes and interferon-stimulated genes. [Abstract]

2026 Jun 13:2026.06.12.731980. PMID: 42327330

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (267.04 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.3407 mL

26.7037 mL

53.4074 mL

5 mM

1.0681 mL

5.3407 mL

10.6815 mL

10 mM

0.5341 mL

2.6704 mL

5.3407 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (534.07 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Consuelo Pasten, et al. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634. [Content Brief]

[2]. Sharon Angela Tanuseputero, et al. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635. [Content Brief]

[3]. Moore WM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994 Nov 11;37(23):3886-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	5.3407 mL	26.7037 mL	53.4074 mL	133.5185 mL
	5 mM	1.0681 mL	5.3407 mL	10.6815 mL	26.7037 mL
	10 mM	0.5341 mL	2.6704 mL	5.3407 mL	13.3518 mL
	15 mM	0.3560 mL	1.7802 mL	3.5605 mL	8.9012 mL
	20 mM	0.2670 mL	1.3352 mL	2.6704 mL	6.6759 mL
	25 mM	0.2136 mL	1.0681 mL	2.1363 mL	5.3407 mL
	30 mM	0.1780 mL	0.8901 mL	1.7802 mL	4.4506 mL
	40 mM	0.1335 mL	0.6676 mL	1.3352 mL	3.3380 mL
	50 mM	0.1068 mL	0.5341 mL	1.0681 mL	2.6704 mL
	60 mM	0.0890 mL	0.4451 mL	0.8901 mL	2.2253 mL
	80 mM	0.0668 mL	0.3338 mL	0.6676 mL	1.6690 mL
	100 mM	0.0534 mL	0.2670 mL	0.5341 mL	1.3352 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

L-NIL

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

L-NIL

1400W Dihydrochloride

L-NAME hydrochloride

GW274150

S-Nitroso-N-acetyl-DL-penicillamine

L-NIO dihydrochloride

DETA NONOate

L-NMMA acetate

Acetylcysteine

L-Canavanine sulfate

2-Iminobiotin

3-Bromo-7-nitroindazole

6-Biopterin

Publications Citing Use of MedChemExpress (MCE) L-NIL

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

L-NIL

1400W Dihydrochloride

L-NAME hydrochloride

GW274150

S-Nitroso-N-acetyl-DL-penicillamine

L-NIO dihydrochloride

DETA NONOate

L-NMMA acetate

Acetylcysteine

L-Canavanine sulfate

2-Iminobiotin

3-Bromo-7-nitroindazole

6-Biopterin

Publications Citing Use of MedChemExpress (MCE) L-NIL

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

L-NIL Related Classifications

HY-12116 Related Classifications

Bioz